Prosonix Elects Dr Ken Cunningham to its Board of Directors Adding Significant Experience in Respiratory Drug Development

04-Oct-2011 - United Kingdom

Prosonix, an emerging pharmaceutical company developing a portfolio of enhanced respiratory medicines enabled by its novel proprietary particle engineering technology, announced that it has elected Dr Ken Cunningham to its Board of Directors as a Non-Executive Director and Chair of its Advisory Board.

Dr Cunningham has over 20 years' experience in the pharmaceutical industry with a strong focus in recent years on respiratory drug development and drug delivery. He is Executive Chairman of PolyTherics Ltd and until August 2010 was CEO of Skyepharma plc. Before that he was Chief Executive Officer of Arakis Ltd, Vice-President European Affairs at Alza Corporation and Vice-President Clinical Development at Sequus Inc. Prior to this he held a variety of clinical development and commercial strategy roles at GlaxoWellcome plc and Warner-Lambert earlier in his career. Ken is also a Non-Executive Director of Xention Ltd. He holds a medical degree from St Mary's, Imperial College, London University.

Other news from the department people

Most read news

More news from our other portals

Fighting cancer: latest developments and advances

Last viewed contents

Novartis announces typhoid vaccine research program in partnership with the Wellcome Trust - New grant from the Wellcome Trust funds progression of vaccine from preclinical through Phase I and II studies with view to protect against both S. Typhi and S. Paratyphi strains

Making sense of what you see in biomedical images - The conventional procedure requires 77 hours, compared to 9 hours with Biomedisa

Making sense of what you see in biomedical images - The conventional procedure requires 77 hours, compared to 9 hours with Biomedisa

Genmab and Seattle Genetics Enter Into Antibody-Drug Conjugate Research Collaboration

Researchers identify neuronal mechanisms that control food cravings during pregnancy - Dopamine and compulsive eating behaviour

Researchers identify neuronal mechanisms that control food cravings during pregnancy - Dopamine and compulsive eating behaviour

Amorfix achieves technical milestone in development of a blood test for Alzheimer's disease

Helén Tuvesson appointed as new Chief Scientific Officer at Active Biotech

Amorfix Life Sciences' test detects scrapie prions in bllod ofg scrapie-infected sheep

Argenta Announces Integrated Drug Discovery Collaboration with Dr. Reddy's Laboratories Ltd

Mice with human antigen presenting molecules demonstrate strong responses to novel melanoma peptide vaccine

Flame retardant ban reduces exposures in pregnant women

Peregrine Enters Contract Negotiations With U.S. DTRA for Hemorrhagic Fevers - U.S. Department of Defense Agency Has Selected Peregrine for a Multi-Year Award That Could Total $44.5 Million Pending Successful Contract Negotiations

Food safety in Europe - who is responsible for what? - BfR publishes 2. completely revised edition of the EU Food Safety Almanac